[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-351836-105":59,"doc-detail-351836-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","oncogenic-kras-driven-type-i-interferon-signalling-primes-pancreatic-cancer-for-necroptosis","Oncogenic KRAS-driven type I interferon signalling primes pancreatic cancer for necroptosis","","Oncogenic KRAS is shown to activate the cGAS-STING-TBK1 axis in pancreatic ductal adenocarcinoma, driving a type I interferon response that primes PDAC cells for necroptosis. Genetically engineered mouse models demonstrate that cancer-cell-specific caspase-8 deletion triggers necroptotic death and eliminates most pancreatic precursor lesions. Mechanistically, KRAS-driven IFN signalling induces ISGF3-dependent expression of necroptosis-related interferon-stimulated genes, including MLKL. Caspase inhibition selectively sensitizes PDAC cells, reducing tumour burden in aggressive models and patient-derived organoids, with transcriptomic analysis linking necroptosis programs to Ras pathway activity and IFN signatures across cancers.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/oncogenic-kras-driven-type-i-interferon-signalling-primes-pancreatic-cancer-for-necroptosis/351836/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/oncogenic-kras-driven-type-i-interferon-signalling-primes-pancreatic-cancer-for-necroptosis/351836.png","ImageObject",300,407,{"name":92,"@type":93},"Aran","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-30","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What role does oncogenic KRAS play in this study’s necroptosis model of PDAC?","Question",{"text":112,"@type":113},"Oncogenic KRAS activates the cGAS-STING-TBK1 axis, leading to a type I interferon response that primes PDAC cells for necroptosis.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How do the mouse experiments establish caspase-8 as a key dependency?",{"text":117,"@type":113},"Cancer-cell-specific deletion of caspase-8 triggers necroptotic cell death, eliminating most pancreatic precursor lesions in genetically engineered mouse models.",{"name":119,"@type":110,"acceptedAnswer":120},"What molecular pathway connects KRAS-driven interferon signalling to necroptosis sensitivity?",{"text":121,"@type":113},"KRAS-driven IFN signalling induces ISGF3-dependent expression of necroptosis-related interferon-stimulated genes, including MLKL, rendering PDAC cells vulnerable to necroptosis when caspase-8 is inhibited.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},351836,1790871617,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},137455076865,"https://ap-avatar.wpscdn.com/davatar_29158cc5080c5b710cf443261637dec0","Article [https://doi.org/10.1038/s41467-026-73189-8](https://doi.org/10.1038/s41467-026-73189-8)  \nOncogenic KRAS-driven type I interferon signalling primes pancreatic cancer for necroptosis  \nReceived: 21 November 2023  \n\n| Accepted: 5 May 2026 |\n| --- |\n| |\n| Check for updates |\n\nSofya Tishina 1,2, Alina Dahlhaus 1,2, Marta Manik 1,2, Lejla Mulalic1,2, Janine Murr 3,4, Michael Kotliar 5, Hassan Rakhsh-Khorshid6,  \nMyrto Kostopoulou1,2, Florian Hocher7, Jenny Stroh1,2, Julia Beck1,2,  \nRiley M. Williams8, Gülce G. Balta 1,2, Fanyu Liu1,2, Ali T. Abdallah2,9, Christina M. Bebber 1,2, Moritz Reese 1,2, Jonathan K. M. Lim10, Alexander Quaas11, Johannes Brägelmann 1,2,12,13, Manolis Pasparakis 2,13,14, Filippo Beleggia 1,2, Siddharth Balachandran 8, Anna Trauzold7,15, Gianmaria Liccardi 6, Igor Astsaturov 16, Maximilian Reichert 3,5,17,18, Ariadne Androulidaki1,2 & Silvia von Karstedt 1,2,13   \nPancreatic ductal adenocarcinoma (PDAC) is projected to become the second leading cause of cancer-related death within this decade. Here, we show that its major driver oncogene KRAS activates the cGAS-STING-TBK1 axis, inducing a type I interferon(IFN)response that primesPDAC cells for necroptosis. Using genetically engineered mouse models, we ﬁnd that cancer cell-speciﬁc deletion of caspase-8 is sufﬁcient to trigger necroptotic cell death, eliminating most pancreatic precursor lesions. Mechanistically, KRAS-driven IFN signalling induces ISGF3-dependent expression of necroptosis-related interferon-stimulated genes, including MLKL. This renders PDAC cells selectively vulnerable to necroptosis upon caspase-8 inhibition. Therapeutically, pharmacologic caspase inhibition reduces tumour burden in aggressive PDAC models and human patient-derived organoids. A pan-cancer transcriptomic analysis links necroptosis gene expression with Ras pathway activity and IFN signatures across multiple tumour types. These ﬁndings reveal a KRAS-induced IFN program that sensitises tumour cellsto necroptosis, highlighting a therapeutic vulnerability in PDAC with broader relevance across IFN-activated cancers.  \nPancreatic ductal adenocarcinoma (PDAC) is among the deadliest cancer entities, and it is expected to become the second leading cause of cancer-related death within this decade1–3. Large research efforts of recent years have described the existence of several molecular subtypes of PDAC4–7 indicating that intra-and interpatient heterogeneity likely complicates effective treatment further. 90% of PDAC cases present with activating point mutations within the proto-oncogene and small GTPase KRAS leading to its constitutive activation and aberrant downstream signalling8. While several studies have identiﬁed  \npromising synthetic lethality targets for cells expressing oncogenic KRAS9, many of these are cytostatic rather than inducing regulated cell death pathways. Notably, expression of oncogenic KRAS protects against oxidative cell death and ferroptosis via upregulation of the cystine/glutamate antiporter xCT10 and ferroptosis suppressor protein 1(FSP1), respectively11. Moreover, cells expressing oncogenic KRAS are known to rewire the extrinsic apoptosis pathway leading to extrinsic apoptosis resistance12,13. Extrinsic apoptosis is triggered through death receptors belonging to the tumour necrosis factor (TNF) receptor  \nA full list of afﬁliations appears at the end of the paper. e-mail: [s.vonkarstedt@uni-koeln.de](s.vonkarstedt@uni-koeln.de)  \n(TNFR)-superfamily14. Upon ligand binding to their cognate receptor, the adaptor molecule Fas associated with a death domain (FADD) is recruited allowing for pro-caspase 8 recruitment and its proximityinduced activation15. The activity of this death-inducing signalling complex (DISC)16 critically depends upon caspase 8 for effective execution of extrinsic apoptosis in mice. Importantly, during mouse development and in healthy adult tissue homeostasis, caspase 8 also protects cells from aberrant necroptosis17–19, a non-apop","cbCaiflsUNwBsnLc","https://ap.wps.com/l/cbCaiflsUNwBsnLc","pdf",7963630,22,"English","# Background\n## KRAS alterations and PDAC lethality\n## Caspase 8 and extrinsic apoptosis versus necroptosis\n# Mechanistic findings\n## cGAS-STING-TBK1 axis activation by KRAS\n## ISGF3-dependent interferon-stimulated necroptosis genes\n# Therapeutic and translational evidence\n## Caspase-8 inhibition sensitizes PDAC to necroptosis\n## Effects in mouse models and patient-derived organoids\n# Broader relevance\n## Pan-cancer transcriptomic links to Ras and IFN signatures","[{\"question\":\"What role does oncogenic KRAS play in this study’s necroptosis model of PDAC?\",\"answer\":\"Oncogenic KRAS activates the cGAS-STING-TBK1 axis, leading to a type I interferon response that primes PDAC cells for necroptosis.\"},{\"question\":\"How do the mouse experiments establish caspase-8 as a key dependency?\",\"answer\":\"Cancer-cell-specific deletion of caspase-8 triggers necroptotic cell death, eliminating most pancreatic precursor lesions in genetically engineered mouse models.\"},{\"question\":\"What molecular pathway connects KRAS-driven interferon signalling to necroptosis sensitivity?\",\"answer\":\"KRAS-driven IFN signalling induces ISGF3-dependent expression of necroptosis-related interferon-stimulated genes, including MLKL, rendering PDAC cells vulnerable to necroptosis when caspase-8 is inhibited.\"}]","Oncogenic KRAS-driven type I interferon signalling primes pancreatic cancer for necroptosis | PDF",1790096259,55,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2fe714b72a210331e38c785ede0b06f8.webp",983,1305,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/bbec2cd8cfe1ddce9159b57f6391ae77.webp",982,1304,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e9d35248714c0460d2f6b45352fd53d3.webp",981,1303,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/28e189a9f7ab850c8ee99a30c5a37049.webp",980,1301]